[2015, July 10th] Submitting your R&D at MEDIT is now eligible for your company to the French CIR tax credit

On July 10th 2015, MEDIT got the the CIR agreement (Credit Impot Recherche) from the Ministère de l'Edutation Nationale, de l'Enseignement Supérieur et de la Recherche, ain reference to article 244 quarter B from tax law book.
Submitting your discovery project to MEDIT r&D opens to your company a tax return up to 30% of the fees engaged with us.


[2014, May 1st] Try for free the FC-Bioisostere(v1.0.8) software for bioisostere replacement

MEDIT is distributing FcBioisostere software from Felix Concordia since 2012. Today we are pleased to provide this access for evaluation: 

(1) download this compress package at http://medit-pharma.com/uploads/media/download/FcBioisostere1.0.8_for_eval.rar ,
(2) uncompress the file ,
(3) open the FcBioisostere1.0.8_for_eval directory ,
(4) double click on FcBioisostere_CLICK_HERE_TO_START .

The RAR compress file for evaluation includes a database of bioisosteres that was built upon the comparison of 4059 kinase pdb files by MED-SuMo . This evaluation version software cannot save results . More about FcBioisostere on http://medit-pharma.com/index.php?page=fc-bioisostere


[2012, March 1st] Medit is distributing FcBioisostere software

MEDIT is becoming a distributor to the FcBioisostere software developed by Felix Concordia SARL company. We recommand to use MED-SuMo for binding site superpositions to generate innovative set of Bioisosteric chemical pairs in FcBioisostere. MEDIT SA and Felix Concordia SARL believe in this new collaboration to provide broader solutions for the benefit of pharma industry.

For chemists and modelers, FC-Bioisostere software opens access to 3D bioisosteric replacement onto your molecule of interest to find chemical groups having similar 3D biological interactions. While maintaining target potencies, it helps you to optimize additional properties in pharmacokinetics and metabolic response, and/or to escape from existing patents by selecting alternative equivalent chemical groups. Please look here to know more about FcBioisostere product.


[2011, Oct 1st] MEDIT eBulletin



[2011, Oct 1st] Computational FBDD videos fin www.medit.fr

A set of videos is describing the computational fragment-based drug design protocol. It is using data and interfaces available in the download section.


[2011, Oct 1st] Fragment (e.g. of a drug) repurposing using MED-SuMo on a full surface PDB protein database

Fragment repurposing by mining protein structures with MED-SuMo is described in a video available in the Learning Center. The results shown are published there: Identify drug repurposing candidates by mining the Protein Data Bank. Moriaud F, Richard SB, Adcock SA, Chanas-Martin L, Surgand J-S, Ben Jelloul M, Delfaud F. Briefings in Bioinformatics Advance Access published April 21, 2011.doi: 10.1093/bib/bbr017.

And the files shown and the Graphical User Interface available for free trial in the download section of this website (please login using a valid email address)


[2011, Oct 1st] Free trial and Training videos in www.medit.fr

Please visite our download page: Download You will find MED-SuMo graphical interface to download. And also some free results to browse for Fragment-Based Drug Design and Fragment (Drug) Repurposing !

You just have to provide a valid email adress !


[2011, April 22nd] New publication: Target-based repurposing of PDB ligands and PDB ligand fragments

Identify drug repurposing candidates by mining the Protein Data Bank


SHORT ABSTRACT
In this review, the target-based drug repurposing using MED-SuMo and the MED-Hybridise platform is described. The software allows browsing of the full surface of all proteins in the Protein Data Bank(PDB) and is capable of detecting site similarities and local similarities. Drug repurposing is described in terms of similar binding sites superpositions and illustrated with the repurposing of drug tadalafil from PDE5A to PDE4A. To investigate the potential of seeking for local similarities, we search a protein kinase hinge region against the full surface of all proteins in the PDB. We then retrieve experimentally validated examples including biotin carboxylase and synapsin with 60 other potential targets. Among them is the HIV-RT allosteric site which is indicating a potential application of fragment repurposing for druggable binding site detection.

KEY POINTS ==> Goto Briefings in bioinformatics website


[2010, Oct 4th] MEDIT SA is proud to announce a strategic collaboration with the Sanford-Burnham Medical Research Institute

MEDIT SA is proud to announce the following strategic collaboration with the Sanford-Burnham Medical Research Institute:

LA JOLLA, Calif., October 4, 2010

Sanford-Burnham Pairs with MEDIT SA to Design Smarter Drugs


Powerful new software matches aberrant proteins with compounds that could fix them.
LA JOLLA, Calif., October 4, 2010 – Scientists at Sanford-Burnham Medical Research Institute (Sanford-Burnham) are collaborating with scientists and software developers at MEDIT SA in France to use and enhance a new software platform built around a computer program called MED-SuMo. This platform searches protein structure databases to find compounds that bind to a particular target, and then helps optimize these “hits” to design new drugs.

“We believe that this collaboration with MEDIT significantly enhances our ability to perform structure-based drug design,” said Nicholas Cosford, Ph.D. associate professor in the Apoptosis and Cell Death Research Program in Sanford-Burnham’s Cancer Center and leader of the collaborative team. “MEDIT’s MED-SuMo software offers unique capabilities that will complement drug discovery platforms already being used in the Conrad Prebys Center for Chemical Genomics [CPCCG] at Sanford-Burnham.”

Here’s how the MEDIT technology works: Sanford-Burnham researchers select a protein they wish to target. Let’s say that this protein, Protein X, normally tells cells to divide, but when it malfunctions, it causes unchecked cell division that leads to a tumor. In an effort to uncover new anti-cancer drugs,  scientists want to find compounds that bind to the deviant Protein X and turn it off. Normally, it might take months or years of work and a stroke of luck to find the one needle-in-a-haystack compound that binds and inhibits Protein X without interfering with other proteins.

Dr. Cosford and his team are taking a more targeted approach to drug design with MEDIT’s software platform. MED-SuMo takes a 3D model of Protein X and breaks it down into pieces. Then the software digs through a publically available database containing more than 60,000 proteins with known structures to find “hits” – pieces that structurally resemble parts of Protein X, but are already known to bind certain compounds. MED-SuMo superimposes the matching hits on the structure of Protein X, allowing researchers to see a 3D image of the interaction. Chemical fragments bound to the hits will bind to Protein X in a similar fashion, forming the initial building blocks for a new drug.

Once MED-SuMo puts these pieces together, MEDIT technology takes drug design several steps further. It can optimize multiple hits by finding ways they could be combined to form a single hybrid drug compound that binds Protein X better and more selectively. The system can even screen out any combinations that couldn’t realistically be generated by chemists in the laboratory, as well as those that might harm other proteins or cause toxicity in humans.

“We’re using MEDIT’s software to look for highly effective drugs,” explained Peter Teriete, Ph.D., post-doctoral researcher in Dr. Cosford’s group. “The great thing about using MED-SuMo at Sanford-Burnham is that we’re also surrounded by drug discovery experts. So if I find something that looks good on the computer, I can work with chemists and assay developers to synthesize the compound in the lab and test it to determine whether or not it has the potential to become a new drug.”

The collaboration goes both ways – Dr. Teriete and others benefit from the software and MEDIT SA’s engineers benefit from their feedback on what works, what could work better, and what additional features would be helpful. Their ideas and experiences will enrich future versions of the MEDIT technology platform, making it an even more powerful tool for drug discovery.

“This agreement with Sanford-Burnham, a leading scientific institution in the U.S., is a great opportunity for our company,” said Stephane Richard, Ph.D., vice president of business development at MEDIT SA. “The collaborative nature of the deal and the involvement of our technology in a number of structure-based drug design efforts will allow researchers at Sanford-Burnham to capitalize on our scientists’ expertise in this field.”

For more information about Sanford-Burnham research, visit http://beaker.sanfordburnham.org/.

 



[2009, Sept 1st] New publication: Computational fragment-based drug design to explore the hydrophobic sub-pocket of the mitotic kinesin Eg5 allosteric binding site

MEDIT presents a new work and results on Computational fragment-based drug design to explore the hydrophobic sub-pocket of the mitotic kinesin Eg5 allosteric binding site by using MED-SuMo to retrieve the best fragments and MED-Hybridise to create new ligands. This article is available on: http://www.springerlink.com/content/w524371333636u72/


[2008, Sept 24th] Sanofi-Aventis acquires MED-Hybridise technology

On September 24th 2008, Sanofi-Aventis decides to use MED-Fragmentor to build the database of MED-Portions (protein-fragments structural object) and MED-Hybridise technology to rationally generate fragment-based chemical compounds by crossing the PDB and chemical supplier databases.


[2008, Sept 22nd] ICSN acquires MED-SuMo technology.

ICSN (Institut de Chimie des Substances Naturelles, Gif sur Yvette, France) decided to use MED-SuMo technology to enhance its work on protein characterization and highlight structural links between proteins. MED-SuMo is a powerful molecular modelling software to compare surface interactions in few minutes toward the PDB (comparison in term of chemical features and shape).


[2008, Sept 15th] MEDIT announces research contract with MUTABILIS biotech

Under the terms of the agreement, MEDIT will apply its molecular modelling expertise on two MUTABILIS targets to provide affinity model to optimise MUTABILIS' proprietary molecules for their anti-infective programs.


[2008, June 27th] New MEDIT website medit-pharma.com

The MEDIT SA website has evolved  from medit.fr to medit-pharma.com on June 27th 2008. The website is entirely new and includes our recent developments (2007/2008) around lead discovery and lead optimization. Please visit applications for MED-SuMo and for our new software MED-Hybridise


[2008, May 28th] MEDIT first release of a pipeline pilot component collection

MEDIT has joined others software editors in the Accelrys Independent Software Vendors (ISV) partner program.
This first release consists of three modules: MED-SuMo server, MED-Hybridise Lead discovery and  MED-Hybridise Lead optimization. The modules facilitate our target based ligand generation protocol: populating a binding site with 3D fragments and generating/optimizing leads. see MED-SuMo in PipelinePilot